Introduction
Type 2 Diabetes is a multifactorial disease that often cannot be managed with monotherapy alone. That’s where SEIZMET GP 1, a triple combination of glimepiride (1 mg), metformin sustained release (500 mg), and pioglitazone (15 mg), comes into play. Developed by Steris Healthcare Pvt. Ltd., this fixed-dose formulation is tailored to target insulin resistance, enhance insulin secretion, and suppress hepatic glucose production—covering all major pathological defects in Type 2 Diabetes.
With growing preference for combination therapy, glimepiride metformin and pioglitazone tablets are now widely recommended by diabetologists and general practitioners alike.
Chemical Composition
Each SEIZMET GP 1 tablet contains:
Glimepiride 1 mg – A second-generation sulfonylurea
Metformin Hydrochloride 500 mg (Sustained Release) – A biguanide antidiabetic
Pioglitazone Hydrochloride 15 mg – A thiazolidinedione
Together, they deliver multi-pronged glycemic control with added benefits in metabolic parameters.
Formulation and Presentation
Dosage Form: Oral tablet
Coating: Film-coated for ease of swallowing and stability
Release Type: Sustained-release for metformin to minimize gastrointestinal side effects
Packaging: Alu-Alu blister pack for enhanced protection and long shelf-life
The fixed-dose combination reduces pill burden, improves compliance, and is ideal for long-term glycemic control.
Mechanism of Action
Glimepiride
Stimulates insulin secretion from pancreatic β-cells and enhances peripheral glucose uptake.
Metformin
Inhibits hepatic gluconeogenesis
Improves insulin sensitivity
Increases peripheral glucose uptake
Reduces intestinal absorption of glucose
Pioglitazone
Activates PPAR-γ receptors in adipose and muscle tissues
Increases insulin sensitivity
Promotes glucose uptake
Enhances lipid metabolism
This triple combination in glimepiride metformin and pioglitazone tablets offers a synergistic mechanism ideal for insulin-resistant patients with uncontrolled diabetes.
Uses and Indications
SEIZMET GP 1 is indicated in:
Type 2 Diabetes Mellitus, especially in patients who:
Are not adequately controlled on metformin or glimepiride alone
Exhibit insulin resistance or metabolic syndrome
Show intolerance to high-dose monotherapy
It helps improve HbA1c, fasting blood glucose, and postprandial blood sugar, while also improving lipid profiles.
Dosage and Administration
Recommended Dose:
1 tablet daily, with food (preferably breakfast)
Adjustments:
Based on glycemic response and tolerance
Initiate cautiously in elderly or renal-impaired patients
Important Notes:
Do not crush or chew
Continue regular exercise and diabetic diet
Monitor blood glucose and HbA1c periodically
Efficacy and Clinical Evidence
Several clinical trials and observational studies have proven that glimepiride metformin and pioglitazone tablets provide:
Significant HbA1c reduction (up to 2.5%)
Enhanced insulin sensitivity
Lower fasting plasma insulin levels
Reduced triglycerides and improved HDL levels
Delay in the need for insulin therapy
The combination has also shown better glycemic durability and long-term control versus dual therapy regimens.
Side Effects and Safety Profile
Common Side Effects:
Hypoglycemia (primarily due to glimepiride)
GI upset (nausea, diarrhea—reduced due to SR metformin)
Weight gain, edema (pioglitazone-related)
Less Common:
Anemia
Liver enzyme elevation
Fluid retention
Risk of heart failure in predisposed individuals
Safety is enhanced with regular monitoring and individualized dosing. The SR formulation of metformin minimizes GI discomfort, making SEIZMET GP 1 a patient-friendly option.
Contraindications and Precautions
Contraindicated in:
Type 1 Diabetes
Diabetic ketoacidosis
Severe renal or hepatic impairmentBladder cancer (pioglitazone-related risk)
Congestive heart failure (NYHA Class III/IV)
Precautions:
Monitor LFTs and renal function
Use cautiously in elderly
Avoid alcohol due to increased risk of lactic acidosis (metformin)
Drug Interactions
May Interact With:
Diuretics
Beta-blockers (may mask hypoglycemia)
Corticosteroids and oral contraceptives (may increase glucose levels)
Alcohol (increases lactic acidosis risk)
Insulin and other sulfonylureas (hypoglycemia risk)
Routine review of concurrent medications is essential for safety.
Warnings and Regulatory Status
Black Box Warning (Pioglitazone): May cause or worsen congestive heart failure
Lactic Acidosis Risk (Metformin): Rare but serious—especially in renal impairment
Regulatory Compliance: Approved under CDSCO guidelines, manufactured in WHO-GMP and ISO-certified facilities
Patient Advice and Lifestyle Tips
Maintain a balanced, low-carb diet
Engage in regular physical activity
Stay hydrated
Monitor for symptoms of hypoglycemia
Avoid smoking and alcohol
Do not skip meals
Follow up regularly with your physician
Empowering patients with these lifestyle tips enhances the overall effectiveness of glimepiride metformin and pioglitazone tablets like SEIZMET GP 1.
Availability
SEIZMET GP 1 is available across:
Retail pharmacies
Hospital procurement channels
Online wholesale platforms
Doctor sample programs (for clinical evaluation)
Contact Steris Healthcare Pvt. Ltd. for stockist/distributor info or institutional supply.
Why Choose Steris Healthcare Pvt. Ltd.?
Steris Healthcare is dedicated to creating affordable, accessible, and clinically effective medications. Here’s why SEIZMET GP 1 is the preferred choice:
Backed by clinical science and years of pharma expertise
GMP and ISO-certified manufacturing for product integrity
Competitive pricing without compromising quality
Comprehensive doctor and patient support programs
Steris believes in responsible diabetes care, and SEIZMET GP 1 reflects that commitment.
Conclusion
The triple therapy of glimepiride, metformin, and pioglitazone is a proven, practical, and patient-friendly approach for managing Type 2 Diabetes Mellitus. With robust clinical backing, a sustained-release formulation, and excellent patient tolerance, SEIZMET GP 1 offers everything you need for effective long-term glycemic control.
Whether you're a clinician looking for a dependable oral regimen or a patient seeking better blood sugar management—glimepiride metformin and pioglitazone tablets like SEIZMET GP 1 offer unmatched value.
Better Control
Fewer Pills
Improved Adherence
Choose SEIZMET GP 1. Choose Confidence. Choose Steris Healthcare.
